|
1
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
von Minckwitz G, Untch M, Nüesch E, Loibl
S, Kaufmann M, Kümmel S, Fasching PA, Eiermann W, Blohmer JU, Costa
SD, et al: Impact of treatment characteristics on response of
different breast cancer phenotypes: Pooled analysis of the German
neo-adjuvant chemotherapy trials. Breast Cancer Res Treat.
125:145–156. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Brugnoli F, Grassilli S, Piazzi M, Palomba
M, Nika E, Bavelloni A, Capitani S and Bertagnolo V: In triple
negative breast tumor cells, PLC-β2 promotes the conversion of
CD133 high to CD133 low phenotype and reduces the CD133-related
invasiveness. Mol Cancer. 12:1652013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Smith LM, Nesterova A, Ryan MC, Duniho S,
Jonas M, Anderson M, Zabinski RF, Sutherland MK, Gerber HP, Van
Orden KL, et al: CD133/prominin-1 is a potential therapeutic target
for antibody-drug conjugates in hepatocellular and gastric cancers.
Br J Cancer. 99:100–109. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pohl A, El-Khoueiry A, Yang D, Zhang W,
Lurje G, Ning Y, Winder T, Hu-Lieskoven S, Iqbal S, Danenberg KD,
et al: Pharmacogenetic profiling of CD133 is associated with
response rate (RR) and progression-free survival (PFS) in patients
with metastatic colorectal cancer (mCRC), treated with
bevacizumab-based chemotherapy. Pharmacogenomics J. 13:173–180.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mizrak D, Brittan M and Alison M: CD133:
Molecule of the moment. J Pathol. 214:3–9. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
McDermott SP and Wicha MS: Targeting
breast cancer stem cells. Mol Oncol. 4:404–419. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Phillips TM, McBride WH and Pajonk F: The
response of CD24(−/low)/CD44+ breast cancer-initiating cells to
radiation. J Natl Cancer Inst. 98:1777–1785. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li X, Lewis MT, Huang J, Gutierrez C,
Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC,
et al: Intrinsic resistance of tumorigenic breast cancer cells to
chemotherapy. J Natl Cancer Inst. 100:672–679. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Creighton CJ, Massarweh S, Huang S,
Tsimelzon A, Hilsenbeck SG, Osborne CK, Shou J, Malorni L and
Schiff R: Development of resistance to targeted therapies
transforms the clinically associated molecular profile subtype of
breast tumor xenografts. Cancer Res. 68:7493–7501. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dontu G, Abdallah WM, Foley JM, Jackson
KW, Clarke MF, Kawamura MJ and Wicha MS: In vitro propagation and
transcriptional profiling of human mammary stem/progenitor cells.
Genes Dev. 17:1253–1270. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lim W, Ko BS, Kim HJ, Lee JW, Eom JS, Son
BH, Lee TJ and Ahn SH: Oncological safety of skin sparing
mastectomy followed by immediate reconstruction for locally
advanced breast cancer. J Surg Oncol. 102:39–42. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Medina-Franco H, Vasconez LO, Fix RJ,
Heslin MJ, Beenken SW, Bland KI and Urist MM: Factors associated
with local recurrence after skin-sparing mastectomy and immediate
breast reconstruction for invasive breast cancer. Ann Surg.
235:814–819. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ren D, Li H, Li R, Sun J, Guo P, Han H,
Yang Y and Li J: Novel insight into MALAT-1 in cancer: Therapeutic
targets and clinical applications. Oncol Lett. 11:1621–1630. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhao Z, Chen C, Liu Y and Wu C:
17β-estradiol treatment inhibits breast cell proliferation,
migration and invasion by decreasing MALAT-1 RNA level. Biochem
Biophys Res Commun. 445:388–393. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bonasio R and Shiekhattar R: Regulation of
transcription by long noncoding RNAs. Annu Rev Genet. 48:433–455.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Harrison H, Farnie G, Howell SJ, Rock RE,
Stylianou S, Brennan KR, Bundred NJ and Clarke RB: Regulation of
breast cancer stem cell activity by signaling through the Notch4
receptor. Cancer Res. 70:709–718. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhao Y, Bao Q, Renner A, Camaj P, Eichhorn
M, Ischenko I, Angele M, Kleespies A, Jauch KW and Bruns C: Cancer
stem cells and angiogenesis. Int J Dev Biol. 55:477–482. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ng JH and Ng HH: LincRNAs join the
pluripotency alliance. Nat Genet. 42:1035–1036. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang A, Zhou N, Huang J, Liu Q, Fukuda K,
Ma D, Lu Z, Bai C, Watabe K and Mo YY: The human long non-coding
RNA-RoR is a p53 repressor in response to DNA damage. Cell Res.
23:340–350. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang Y, Xu Z, Jiang J, Xu C, Kang J, Xiao
L, Wu M, Xiong J, Guo X and Liu H: Endogenous miRNA sponge
lincRNA-RoR regulates Oct4, Nanog and Sox2 in human embryonic stem
cell self-renewal. Dev Cell. 25:69–80. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kallen AN, Zhou XB, Xu J, Qiao C, Ma J,
Yan L, Lu L, Liu C, Yi JS, Zhang H, et al: The imprinted H19 lncRNA
antagonizes let-7 microRNAs. Mol Cell. 52:101–112. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gutschner T, Hämmerle M and Diederichs S:
MALAT1-a paradigm for long noncoding RNA function in cancer. J Mol
Med (Berl). 91:791–801. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jiao F, Hu H, Han T, Yuan C and Wang L,
Jin Z, Guo Z and Wang L: Long noncoding RNA MALAT-1 enhances stem
cell-like phenotypes in pancreatic cancer cells. Int J Mol Sci.
16:6677–6693. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Al-Hajj M, Wicha MS, Benito-Hernandez A,
Morrison SJ and Clarke MF: Prospective identification of
tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 100:pp.
3983–3988. 2003; View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hermann PC, Huber SL, Herrler T, Aicher A,
Ellwart JW, Guba M, Bruns CJ and Heeschen C: Distinct populations
of cancer stem cells determine tumor growth and metastatic activity
in human pancreatic cancer. Cell Stem Cell. 1:313–323. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Schmidt LH, Spieker T, Koschmieder S,
Schäffers S, Humberg J, Jungen D, Bulk E, Hascher A, Wittmer D,
Marra A, et al: The long noncoding MALAT-1 RNA indicates a poor
prognosis in non-small cell lung cancer and induces migration and
tumor growth. J Thorac Oncol. 6:1984–1992. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lai MC, Yang Z, Zhou L, Zhu QQ, Xie HY,
Zhang F, Wu LM, Chen LM and Zheng SS: Long non-coding RNA MALAT-1
overexpression predicts tumor recurrence of hepatocellular
carcinoma after liver transplantation. Med Oncol. 29:1810–1816.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ren S, Wang F, Shen J, Sun Y, Xu W, Lu J,
Wei M, Xu C, Wu C, Zhang Z, et al: Long non-coding RNA metastasis
associated in lung adenocarcinoma transcript 1 derived miniRNA as a
novel plasma-based biomarker for diagnosing prostate cancer. Eur J
Cancer. 49:2949–2959. 2013. View Article : Google Scholar : PubMed/NCBI
|
